Modest results from a federal trial of an experimental drug helped send the stock market soaring on Wednesday, another sign of the desperation for a viable treatment against the coronavirus. Just before markets opened, Gilead, maker of the antiviral drug remdesivir, announced that it was “aware of positive data” about the drug’s performance in a […]

This story is from The Seattle Times. Read the rest of this News story at https://www.seattletimes.com/nation-world/remdesivir-shows-modest-benefits-in-coronavirus-trial/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_seattle-news.

This post was originally published on this site